Meril Life Sciences Presents One-year Outcomes from the LANDMARK Randomised Controlled Trial at PCR London Valves 2025

Meril Life Sciences has shared one-year outcomes from the pivotal LANDMARK RCT at PCR London Valves 2025, confirming comparable efficacy and superior extended clinical outcomes for the Myval THV series alongside the lowest regurgitation rates among leading transcatheter valves.

London, November 16, 2025 – Meril Life Sciences today presented the one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) during the Late-Breaking Trial sessions at PCR London Valves 2025, a globally recognized structural heart conference. The LANDMARK trial represents the first-ever multicenter RCT to directly compare the balloon-expandable Myval THV series with both the balloon-expandable Sapien THV series and the self-expanding Evolut THV series in patients with symptomatic severe aortic stenosis.

At one-year, the Myval THV series demonstrated comparable composite clinical efficacy, defined as freedom from all-cause mortality, all stroke, and procedure- or valve-related hospitalization, when compared to the Sapien and Evolut THV series, with outcomes reported at 87% for Myval THV Series, 86.9% for Sapien THV series, and 86.9% for Evolut THV series.